Professor Landray seeks to further understand the determining factors in common life-threatening and disabling diseases through the design, conduct and analysis of efficient, large-scale epidemiological studies, including clinical trials.
He leads international trials that have enrolled over 65,000 individuals with cardiovascular or kidney disease from 18 countries across 4 continents, and the results of completed studies have changed regulatory drug approvals, influenced clinical guidelines and changed prescribing practice to the benefit of patients. He also oversees the development of systems for recruitment, data collection (including integrated measurement devices and record linkage), analysis and data sharing for UK Biobank, a prospective cohort study of 500,000 middle-aged men and women.
He is also heavily involved in efforts to streamline clinical trials, working with national and international organizations (including FDA, EMA, MHRA, MRC) to facilitate high quality research is efficient in providing robust information for healthcare decision-making. He is a member of the Steering Committee of the Clinical Trial Transformation Initiative (a FDA initiative, coordinated by Duke University) and a leader of the CTTI Monitoring and Quality by Design Projects. He was previously an advisor to the FDA’s initiative to develop standardized definitions for cardiovascular endpoints in clinical trials, a member of the NIHR Commissioning Board, and a member of a UK Department of Health / MRC / MHRA project to promote risk-based monitoring of clinical trials.
He is also a practising hospital consultant, working in the Department of Cardiology at the John Radcliffe Hospital.
- Clinical trials
- Big Data and its applications for health
- Heart disease
- Kidney disease
- Population health
- Disease prevention
Professor Landray has experience in dealing with the media, including television, radio and print.